Dr. Pooja Babbar
Gurgaon: In the rapidly evolving world of cancer care, precision, timeliness, and personalized treatment have become the pillars of effective therapy. Leading this transformation is Dr. Pooja Babbar, a highly qualified oncologist with over 15 years of experience and international certifications. She is at the forefront of a breakthrough in cancer diagnostics: Liquid Biopsies 2.0, a revolutionary approach that is changing how oncologists monitor and manage cancer.
Unlike conventional tissue-based biopsies, Liquid Biopsies 2.0 are blood-based, minimally invasive, and faster, allowing doctors to track tumors in real time. Dr. Babbar explains that these tests enable a detailed examination of circulating tumor DNA, tumor cells, and other biomarkers in a blood sample, providing a comprehensive picture of the patient’s condition. What sets this technology apart is its ability to deliver continuous, personalized monitoring, often detecting treatment responses long before traditional imaging or scans can.
Redefining Cancer Monitoring
One of the most significant advantages of Liquid Biopsies 2.0 is the detection of minimal residual disease (MRD) — small clusters of cancer cells that may remain after surgery or chemotherapy. These residual cells often lead to recurrence, but periodic blood testing allows oncologists to identify them early and intervene with additional therapy when needed. According to Dr. Babbar, this continuous feedback enables clinicians to modify treatment plans promptly, ensuring that every patient receives the right therapy at the right time.
Precision Oncology in Practice
Liquid Biopsies 2.0 are also instrumental in advancing precision oncology. By identifying the tumor’s specific genetic mutations, oncologists can choose targeted therapies with higher effectiveness. Moreover, if the tumor evolves or develops resistance, blood tests provide early warning, guiding adjustments in medication or consideration for clinical trials. This approach significantly reduces uncertainty and ensures that treatment is aligned with the patient’s unique cancer biology.
Dr. Babbar believes these developments mark a turning point in oncology. “Liquid Biopsies 2.0 give doctors the power to stay one step ahead of cancer,” she says. The technology not only makes treatment safer and more convenient for patients but also equips oncologists with deeper insights and greater flexibility in managing therapy.
Through her expertise and advocacy for innovative cancer care, Dr. Pooja Babbar is redefining the future of oncology, ensuring that patients receive care that is proactive, personalized, and precise — a true paradigm shift in cancer treatment.
Disclaimer: This press release is for general information purposes only and should not be construed as professional medical advice. Always consult a doctor before taking any decisions.
